Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1

Status

Active not recruiting 3Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 15Lymphoid 11Myeloid 5Genitourinary 3Plasma cell 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Philadelphia Chromosome 1Myeloproliferative Disorders 1Blast Crisis 1

Interventions

fludarabine 30Specimen Handling 28Cyclophosphamide 27Azacitidine 23venetoclax 22fludarabine phosphate 22Biopsy 22ruxolitinib 18Whole-Body Irradiation 17Cytarabine 17Mycophenolic Acid 16Busulfan 16asciminib 15Tacrolimus 15Melphalan 14Injections 12Decitabine 12decitabine and cedazuridine drug combination 11X-Rays 11Magnetic Resonance Spectroscopy 11Stem Cell Transplantation 10Granulocyte Colony-Stimulating Factor 10Sirolimus 9Peripheral Blood Stem Cell Transplantation 9Cyclosporine 9Thiotepa 8Filgrastim 8nilotinib 7Imatinib Mesylate 7Phantoms, Imaging 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Dasatinib × Myeloid × 90 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00070499 2026-05-29

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
406 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07269470 2026-05-05

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04626024 2026-05-04

TOKIN

Baylor College of Medicine

Phase 2 Active not recruiting
17 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡